GCM
STRO icon

Graham Capital Management’s Sutro Biopharma STRO Stock Holding History

Graham Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,114
Closed -$73.1K – 1469
2024
Q3 		$73.1K Buy
+2,114
New +$82.9K ﹤0.01% 1025
2022
Q3 		– Sell
-25,192
Closed -$1.31M – 1312
2022
Q2 		$1.31M Buy
+25,192
New +$1.41M 0.05% 345

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Graham Capital Management's STRO Position: Q4 2024 in Review

Graham Capital Management sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 2,114 shares — an estimated $73.1K sold.

Graham Capital Management first reported a position in STRO in Q2 2022 and held it in 2 quarters. The position peaked at $1.31M in Q2 2022. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • Graham Capital Management reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • Graham Capital Management sold 2,114 Sutro Biopharma shares in Q4 2024, an estimated $73.1K.
  • Graham Capital Management first reported a position in Sutro Biopharma in Q2 2022 and held it in 2 quarters.
  • Graham Capital Management's Sutro Biopharma position peaked at $1.31M in Q2 2022.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on Graham Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.